China News Service, Beijing, September 22 (Reporter Xia Bin) On the 22nd, the three "demon stocks" on the A-share GEM, Tianshan Biology, Changfang Group, and Yudiamond, resumed trading at the same time, but they all met their limit at the opening day. .

　　The previous day’s evening, the China Securities Regulatory Commission announced that recently, the stock prices of “Tianshan Biological” and other stocks fluctuated abnormally in the short term, and the market paid great attention.

Recently, the China Securities Regulatory Commission has filed an investigation on the abnormal transactions.

In the next step, the China Securities Regulatory Commission will deal with it in accordance with the law on the basis of a comprehensive investigation to effectively maintain the healthy and stable development of the market.

　　Tianshan Biotech and other ChiNext stocks have soared before, and have repeatedly touched abnormal fluctuations in stock trading.

The Shenzhen Stock Exchange pointed out that a small number of ChiNext stocks with small circulating market capitalization, low prices, and poor fundamentals, such as Tianshan Biological, Yu Diamond, and Changfang Group, have seen their stock prices rise rapidly in the short term, and speculation is more prominent.

　　Tianshan Biological, Changfang Group, and Yu Diamond were required by the Shenzhen Stock Exchange to suspend trading for verification. Judging from the latest suspension verification results and resumption announcements of the three companies, there are many risks.

　　Tianshan Biological has exposed the company’s 9 major risks, including secondary market transaction risks. At the same time, the company’s price-to-book ratio is significantly higher than the industry average; Zheshang Bank has sued Elephant Advertising for repayment of borrowings and required the company to perform guarantee obligations; capital chain The risk of tension, etc.

　　Changfang Group said that the company currently has six major risks such as operation, impairment of goodwill, and capital turnover; Yu Diamond also detailed 11 risks such as performance loss and litigation in the announcement. Among them, the company was approved by the China Securities Regulatory Commission in April 2020. A case will be filed for investigation, and the case has not yet been closed.

(Finish)